Outcomes of adults with cirrhosis admitted to the general ICU (2014–2024)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a regional retrospective multicentre cohort analysis of adult patients with cirrhosis admitted to general intensive care units between January 2014 and December 2024. Medical records from a tertiary centre (CHU de Besançon) and affiliated primary hospitals will be reviewed for admission severity, ICU interventions, application of guideline-based practices, access to liver transplantation, and outcomes including survival. The analysis will compare current outcomes and care practices with data reported in the literature prior to 2014 and will look for variability in patient phenotype and outcomes related to centre resources. No prospective interventions are planned; all adults with clinically or histologically confirmed cirrhosis admitted during the period are eligible for inclusion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with cirrhosis over 18 years of age (cirrhosis either histologically proven or diagnosed by hepatologists according to clinical, biological and ultrasound criteria) admitted to intensive care between January 2014 and December 2024.

Exclusion Criteria:

None

Where it's running

• CHU de Besançon
  Besançon, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis

  This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.

  Recruiting University Medical Center Ho Chi Minh City (UMC) · Ho Chi Minh City · NCT07918378

• EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis

  This trial tests whether using endoscopic ultrasound to guide coils plus glue works better than glue alone for stopping bleeding from gastric varices in adults with cirrhosis.

  Recruiting Medanta, The Medicity, India · Orlando, Florida and 1 other locations · NCT07855913

• Gut microbes and blood signals in sepsis-related liver and kidney injury

  This study tests whether gut microbes and blood markers differ in adults with sepsis who develop liver or kidney injury, compared with healthy volunteers.

  Recruiting at 6 sites First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 5 other locations · NCT07735182

• 4D-Flow MRI to see portal hypertension and TIPS outcomes in cirrhosis

  This study tests a noninvasive 4D-Flow MRI method to see if it can safely and reliably reflect portal hypertension and predict outcomes for people with cirrhosis, including those needing a TIPS procedure.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07554183

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

• Factors that affect reopening of blocked portal veins in people with cirrhosis and gastroesophageal varices

  This project looks at past records and follow-up to see which factors are linked with reopening (recanalization) of blocked portal veins in people who have cirrhosis and endoscopy-confirmed gastroesophageal varices.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07473375

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.